← All trials
NCT04303026
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 2, 2020
- Primary completion
- Mar 15, 2021
- Completion date
- Mar 15, 2022
- First posted
- Mar 10, 2020
- Last posted
- Mar 10, 2020
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Martina Hansen's HospitalLead sponsor
- South-Eastern Norway Regional Health AuthorityStudy director
- University of OsloCollaborator
- University of OsloCollaborator
- Martina Hansen's HospitalReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.